GWM
KRYS icon

Gilpin Wealth Management’s Krystal Biotech KRYS Stock Holding History

Gilpin Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-3
Closed -$1.12K – 1452
2026
Q2 		$1.12K Sell
3
-1
-25% -$299 ﹤0.01% 495
2026
Q1 		$1.03K Buy
4
+2
+100% +$532 ﹤0.01% 471
2025
Q4 		$494 Buy
+2
New +$421 ﹤0.01% 454

Other funds holding KRYS

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Gilpin Wealth Management's KRYS Position: Q3 2026 in Review

Gilpin Wealth Management sold out of Krystal Biotech (KRYS) in Q3 2026, closing a stake of 3 shares — an estimated $1.12K sold.

Gilpin Wealth Management first reported a position in KRYS in Q4 2025 and held it in 3 quarters. The position peaked at $1.12K in Q2 2026. 11 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Gilpin Wealth Management reported no remaining Krystal Biotech position as of Q3 2026 after selling out during the quarter.
  • Gilpin Wealth Management sold 3 Krystal Biotech shares in Q3 2026, an estimated $1.12K.
  • Gilpin Wealth Management first reported a position in Krystal Biotech in Q4 2025 and held it in 3 quarters.
  • Gilpin Wealth Management's Krystal Biotech position peaked at $1.12K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.